Copyright
©The Author(s) 2022.
World J Clin Cases. Feb 6, 2022; 10(4): 1164-1171
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1164
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1164
Table 3 Incidences of adverse events, n (%)
| AEs | Any grade | Grade III and above |
| Decreased hemoglobin | 34 (75.6) | 5 (11.1) |
| Leukopenia | 16 (35.6) | 0 (0) |
| Thrombocytopenia | 14 (31.1) | 1 (2.2) |
| Elevated transaminase | 24 (53.3) | 7 (15.6) |
| Nausea/vomiting | 32 (71.1) | 0 (0) |
| Constipation | 1 (3.4) | 0 |
- Citation: Qin ZQ, Yang SF, Chen Y, Hong CJ, Zhao TW, Yuan GR, Yang L, Gao L, Wang X, Lu LQ. Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer. World J Clin Cases 2022; 10(4): 1164-1171
- URL: https://www.wjgnet.com/2307-8960/full/v10/i4/1164.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i4.1164